Roche Renews Internal Research License for Patented Gene Targeting Technology From Lexicon Genetics
Tuesday December 21, 8:30 am ET
THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Roche Palo Alto LLC has renewed its license agreement for non-exclusive rights under patents controlled by Lexicon covering gene targeting technologies for the generation of knockout mice. The renewed license will provide Roche with continued rights under patents covering the technologies frequently referred to as "isogenic DNA" and "positive-negative selection" to generate and use knockout mice in its internal drug discovery research. Financial terms of the agreement were not disclosed.
ADVERTISEMENT
"We are pleased that Roche has elected to extend its access to our patented gene targeting technologies," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "We have 12 major pharmaceutical sublicensees to this technology, yet another indicator of the importance of gene knockouts in drug discovery."
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, cancer, immune system disorders, ophthalmic disease, and psychiatric and neurological disorders. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, lexicon-genetics.com .
Safe Harbor Statement
This press release contains |
